MBRX revenueQ2 2026$0
MBRX revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Moleculin Biotech Inc. (MBRX) financials
For the twelve months ended Jun 30, 2026, Moleculin Biotech Inc. reported $0 of revenue and -$30.33M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$30.33M
- Cash
- $7.26M
- Market cap
- $9.1M
FY2016FY2025
FY2016FY2025
FY2016FY2025
MBRX revenue and earnings growth
MBRX net incomeQ2 2026-$7.63M
MBRX net income was -$7.63M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$17.81M a year earlier. For the full fiscal 2025 it was -$33.56M, compared with -$26.05M in fiscal 2024.
MBRX free cash flowQ4 2025-$5.37M
MBRX free cash flow was -$5.37M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$5.08M a year earlier. For the full fiscal 2025 it was -$22.73M, compared with -$23.88M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $15.89M | $17.73M | $19.49M | $18.97M | $14.42M | $12.76M | $11.01M | $9.73M | $4.54M | $1.50M |
| Selling, general and admin | $9.12M | $8.79M | $10.02M | $11.54M | $8.39M | $6.79M | $6.31M | $5.23M | $4.09M | $2.38M |
| Operating income | -$25.10M | -$26.64M | -$29.63M | -$30.64M | -$22.97M | -$19.74M | -$17.52M | -$15.03M | -$8.65M | -$3.88M |
| Interest expense | - | - | - | - | - | - | - | - | $0 | $43.0K |
| Pre-tax income | -$33.56M | -$26.05M | - | - | - | -$17.36M | -$13.43M | - | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$229.0K | $0 | $0 | $0 |
| Net income | -$33.56M | -$26.05M | -$29.77M | -$29.02M | -$15.89M | -$17.36M | -$13.21M | -$11.88M | -$9.80M | -$3.93M |
| EPS, basic | -$28.42 | -$189.14 | -$15.07 | -$15.22 | -$0.59 | -$1.76 | -$1.95 | -$2.76 | -$3.18 | -$2.40 |
| EPS, diluted | - | - | - | - | -$0.59 | -$1.76 | -$1.95 | -$2.76 | -$3.18 | -$2.40 |
| Diluted shares | - | - | - | - | 26.9M | 9.8M | 6.8M | 4.3M | 3.1M | 1.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.88M | $4.28M | $23.55M | $43.15M | $70.90M | $15.17M | $10.73M | $7.13M | $7.71M | $5.01M |
| Receivables | - | - | - | - | - | - | $1.0K | $56.0K | - | - |
| Current assets | $9.69M | $5.19M | $26.27M | $45.60M | $72.50M | $17.20M | $13.48M | $7.97M | $8.30M | $5.22M |
| Total assets | $22.13M | $16.93M | $38.22M | $57.42M | $84.09M | $29.03M | $25.23M | $19.59M | $19.48M | $16.39M |
| Current liabilities | $6.85M | $5.36M | $6.82M | $4.82M | $3.62M | $2.92M | $3.57M | $3.88M | $2.21M | $1.34M |
| Total liabilities | $7.12M | $5.72M | $12.14M | $5.23M | $5.10M | $11.27M | $9.66M | $5.31M | $2.37M | $1.43M |
| Shareholders' equity | $15.01M | $11.21M | $30.93M | $52.19M | $78.99M | $17.76M | $15.57M | $14.27M | $17.12M | $14.96M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.73M | -$23.86M | -$23.59M | -$27.64M | -$18.95M | -$17.77M | -$17.20M | -$12.20M | -$7.32M | -$3.77M |
| Capital expenditures | $0 | $13.0K | $124.0K | $67.0K | $19.0K | $376.0K | $52.0K | $417.0K | $28.0K | $21.0K |
| Free cash flow | -$22.73M | -$23.88M | -$23.71M | -$27.71M | -$18.97M | -$18.15M | -$17.25M | -$12.62M | -$7.35M | -$3.79M |
| Investing cash flow | $0 | -$13.0K | -$124.0K | -$67.0K | -$19.0K | -$374.0K | -$51.0K | -$417.0K | -$28.0K | -$121.0K |
| Financing cash flow | $27.28M | $4.63M | $4.14M | -$23.0K | $74.72M | $22.55M | $20.85M | $12.04M | $10.06M | $8.87M |
| Stock-based compensation | $1.66M | $1.73M | $1.98M | $2.27M | $2.37M | $1.68M | $1.54M | $1.14M | $707.0K | $324.0K |
| Depreciation and amortization | $90.0K | $126.0K | $127.0K | $130.0K | $164.0K | $200.0K | $199.0K | $68.0K | $18.0K | $6.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -223.6% | -232.4% | -96.3% | -55.6% | -20.1% | -97.7% | -84.8% | -83.2% | -57.3% | -26.2% |
| Return on assets | -151.7% | -153.9% | -77.9% | -50.5% | -18.9% | -59.8% | -52.3% | -60.6% | -50.3% | -23.9% |
| Current ratio | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 | 3.78 | 2.06 | 3.75 | 3.88 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $5.45M | $5.38M | $5.12M | $3.74M | $3.60M | $3.44M | $4.46M | $4.93M | $4.09M | $4.25M | $6.63M | $3.28M |
| Selling, general and admin | $2.10M | $2.49M | $2.41M | $2.15M | $2.09M | $2.48M | $2.16M | $2.17M | $2.06M | $2.39M | $2.25M | $2.63M |
| Operating income | -$7.56M | -$7.87M | -$7.53M | -$5.91M | -$5.72M | -$5.94M | -$6.64M | -$7.13M | -$6.18M | -$6.68M | -$8.92M | -$5.95M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.63M | -$12.85M | $15.55M | -$25.40M | -$17.81M | -$5.90M | -$6.58M | -$7.02M | -$6.01M | -$6.42M | -$10.27M | -$5.61M |
| EPS, basic | -$1.40 | -$3.54 | - | -$0.68 | -$28.68 | -$15.80 | - | -$1.89 | -$2.37 | -$2.61 | - | -$2.82 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.26M | $10.32M | $8.88M | $6.70M | $7.56M | $7.72M | $4.28M | $9.40M | $10.85M | $16.82M | $23.55M | $24.58M |
| Current assets | $8.72M | $10.96M | $9.69M | $7.88M | $9.08M | $9.34M | $5.19M | $11.61M | $13.73M | $18.96M | $26.27M | $27.60M |
| Total assets | $21.09M | $23.36M | $22.13M | $20.35M | $21.59M | $21.01M | $16.93M | $23.39M | $25.57M | $30.84M | $38.22M | $39.52M |
| Current liabilities | $9.31M | $7.96M | $6.85M | $5.68M | $7.91M | $6.90M | $5.36M | $5.59M | $5.75M | $5.41M | $6.82M | $3.89M |
| Total liabilities | $9.50M | $8.18M | $7.12M | $47.27M | $25.18M | $7.22M | $5.72M | $15.91M | $7.87M | $9.26M | $12.14M | $4.38M |
| Shareholders' equity | $11.59M | $15.18M | $15.01M | -$26.92M | -$3.6K | $13.79M | $11.21M | $17.41M | $19.41M | $24.99M | $30.93M | $35.14M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.66M | -$6.11M | -$5.37M | -$7.22M | -$5.58M | -$4.56M | -$5.08M | -$6.11M | -$5.95M | -$6.72M | -$4.90M | -$7.55M |
| Capital expenditures | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $13.0K | $0 | $81.0K | $28.0K |
| Free cash flow | - | - | -$5.37M | -$7.22M | -$5.58M | -$4.56M | -$5.08M | -$6.11M | -$5.96M | -$6.72M | -$4.98M | -$7.58M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$13.0K | $0 | -$81.0K | -$28.0K |
| Financing cash flow | $3.61M | $7.61M | $7.49M | $6.38M | $5.42M | $8.00M | $1.0K | $4.66M | -$25.0K | $0 | $3.96M | -$4.0K |
| Stock-based compensation | $436.0K | $380.0K | $459.0K | $303.0K | $417.0K | $485.0K | $427.0K | $353.0K | $453.0K | $493.0K | $479.0K | $493.0K |
| Depreciation and amortization | $8.0K | $8.0K | $9.0K | $21.0K | $29.0K | $31.0K | $31.0K | $31.0K | $31.0K | $32.0K | $35.0K | $32.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.94 | 1.38 | 1.41 | 1.39 | 1.15 | 1.35 | 0.97 | 2.08 | 2.39 | 3.51 | 3.86 | 7.10 |
Source: XBRL data Moleculin Biotech Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-6, first reported Mar 24, 2021.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MBRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MBRX | $0 | - | -$30.33M | - | $9.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
MBRX FAQ
5 questionsWhat is MBRX revenue?
Moleculin Biotech Inc. (MBRX) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $0.Is MBRX profitable?
No. Moleculin Biotech Inc. reported a net loss of $30.33M for the twelve months ended Jun 30, 2026.How much cash and debt does MBRX have?
Moleculin Biotech Inc. reported $7.26M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did MBRX last report financial results?
The latest statements here come from Moleculin Biotech Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this MBRX financial data come from?
Quantisnow builds these statements from the structured XBRL data Moleculin Biotech Inc. files with the SEC. It is provided for information only and is not investment advice.